Midazolam

證據等級: L5

預測適應症: 1 個

Midazolam: From Procedural Sedation to Insomnia

One-Sentence Summary

Midazolam is a short-acting benzodiazepine best known for procedural sedation, anaesthesia induction, and ICU sedation. The TxGNN model predicts it may be effective for Insomnia, with a prediction score of 99.74%, though the supporting evidence is largely older, small-scale trials and indirect sedation/ICU studies rather than modern chronic-insomnia RCTs.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack — no SAHPRA-approved indication text on file (drug not marketed in South Africa). Midazolam is internationally established as a short-acting sedative/hypnotic used for procedural sedation, anaesthesia induction, and ICU sedation.
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.74%
Evidence Level	L2
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Midazolam is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, enhancing chloride channel activity to produce sedative and hypnotic effects. Mechanistically, this places it in direct pharmacological continuity with insomnia treatment, since GABA-A potentiation is the same target class used by established hypnotics (e.g., benzodiazepine and Z-drug sleep aids).

However, midazolam’s short half-life (approximately 1.5–2.5 hours) means it is currently used almost exclusively for procedural sedation, anaesthesia induction, and ICU sedation rather than sustained overnight sleep maintenance. This short-acting profile can lead to rebound insomnia and withdrawal-type symptoms, and current insomnia treatment guidelines (e.g., AASM) do not recommend it as first-line therapy for chronic insomnia. The prediction is therefore mechanistically reasonable but clinically constrained by pharmacokinetics, dependence potential, and respiratory depression risk — consistent with why the evidence pipeline classified this as a Hold at decision stage S1.

Clinical Trial Evidence

A total of 32 clinical trials were retrieved for the midazolam–insomnia query; most involve midazolam only as a comparator or component of perioperative/ICU sedation regimens rather than as a primary treatment for chronic insomnia. The two trials below were graded most directly relevant:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06407518	N/A	Recruiting	280	Preoperative oral midazolam evaluated for postoperative pain in colorectal cancer surgery patients with pre-existing sleep disturbance/anxiety; midazolam oral solution noted as safe/effective for short-term hypnosis in this context.
NCT02142595	Phase 4	Completed	111	IV midazolam vs dexmedetomidine sedation compared for postoperative sleep quality after TURP surgery.

The remaining ~30 trials (e.g., dexmedetomidine-vs-midazolam ICU/pediatric sedation comparisons, acupuncture, noise-reduction, and non-pharmacological sleep-quality studies) were graded as indirect (procedural/ICU context, not chronic insomnia) or have not yet completed relevance triage — none directly evaluate midazolam as a primary chronic insomnia therapy.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6138072	1983	RCT	Br J Clin Pharmacol	Midazolam 15mg vs Vesparax in 30 women with insomnia secondary to neuromuscular disease; both effective hypnotics, midazolam better tolerated with no hangover effect.
2121802	1990	RCT	J Clin Psychopharmacol	Multicenter 14-day study of flurazepam vs midazolam in chronic insomniacs, examining sleep, daytime performance, and plasma levels.
6120704	1981	RCT	Arzneimittelforschung	Dose-finding study of oral midazolam (10–30mg) in 75 patients with mild-to-moderate insomnia; established optimal dose range.
2229461	1990	RCT	J Clin Psychopharmacol	Executive summary of the multicenter 14-day flurazepam vs midazolam chronic insomnia trial.
2883820	1986	Review	Acta Psychiatr Scand Suppl	Overview of hypnotic classes including benzodiazepines, noting differing pharmacokinetic profiles relevant to insomnia subtypes.
17988972	2007	Review	Orvosi Hetilap	General review of insomnia pathophysiology and classification (primary vs secondary).
36912148	2024	Review	Am J Hosp Palliat Care	End-of-life symptom management cases referencing midazolam use for sedation, not chronic insomnia treatment.
36615100	2022	Cohort	J Clin Med	Lemborexant (non-benzodiazepine) evaluated as insomnia treatment to avoid delirium risk associated with benzodiazepines in high-risk endoscopy patients.
22729271	2013	Preclinical	Psychopharmacology	Zolpidem (benzodiazepine-class hypnotic) effects on sedation, anxiety, and memory in an animal model.
21396773	2011	Preclinical	Pain	GABAergic transmission changes linked to sleep disturbance in a neuropathic pain mouse model, supporting the GABA-A mechanistic pathway.

South Africa Market Information

Midazolam currently has no SAHPRA product registrations on file (0 licences); market status is recorded as Not Marketed in South Africa.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA. (Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack — see Next Steps.)

Conclusion and Next Steps

Decision: Hold

Rationale: The GABA-A mechanism is directly relevant to insomnia, and older small-scale RCTs (1981–1990) support short-term hypnotic efficacy of oral midazolam. However, its short half-life makes it unsuitable for chronic insomnia per current guidelines, no modern trials directly target chronic insomnia as a primary endpoint, and critical safety data (PI warnings/contraindications) are unavailable.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain SAHPRA/TFDA-approved Professional Information (warnings, contraindications) before any S1 safety assessment can proceed
Resolve DG002 (High): obtain confirmed mechanism-of-action and original-indication documentation from DrugBank
Clarify intended clinical positioning (short-term/situational insomnia vs. chronic insomnia) given dependence, rebound, and respiratory depression risks
Assess regulatory pathway feasibility given midazolam is not currently marketed in South Africa (0 SAHPRA registrations)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.